How are biotech investors doing?

XBI -30% YTD after coming off a rough 2H 2021. Anyone have any data points or anecdotes on how biotech funds are doing so far this year? I understand a couple of the brand name funds were down 70%+ last year and liquidated, but I’ve heard little this year about the situation. XBI continues to hit new 52-week lows so would be curious to hear want sentiment and job security is like right now.

 

Heavy investments into MXCT/VRTX have saved my portfolio gradually moving my VRTX weight into MXCT. The rest of the biotech space well, my portfolio is in pain.

 
Most Helpful

So all I have is secondhand anecdotal information, but I was working on a capital raise in late Q3 2021 and a PM at a fund we have a good relationship with told us some pretty brutal performance #s while we were on a call with them for the deal (in a sort of "we like this deal but doubt you'll get this done because all the funds are getting smoked right now" kind of way). I can't imagine that they have gotten any better either since. The ones he listed were:

RTW: down ~40%

Perceptive: down ~30%

Casdin: down ~45% (I also heard that LPs were super pissed at them since they personally sponsored their SPACs instead of the promote going to the fund)

A friend of mine in biotech equity research told me Logos totally blew up - not 100% sure but I haven't seen them do any deals recently

Tang: more of a family office than a fund but between Odonate, LJPC, HRTX, etc. blowing up, Kevin is in a real liquidity crunch, wouldn't surprise me if he's down >75%.

BlackRock: you can see the performance of their ETFs in the market - they write plenty of checks out of funds like BMEZ, which is down ~40% in the last year.

Orbimed: supposedly down >40% as of November per this article https://www.wsj.com/articles/hedge-funds-suffer-big-losses-on-biotech-r…

Cormorant: down ~40%

Consonance closed their public markets hedge fund

I'm sure Surveyor/Citadel is getting massacred too - they were throwing money into everything and were drawing down deeply into Citadel's pockets.

All the numbers above were as of 3-6 months ago. Wouldn't be surprised if they have crossed the 50% loss threshold. It's a slaughter out there. Not to mention, a lot of these funds have substantial private company portfolios that probably aren't being properly marked to market either, so the losses are likely understated.

 

These are for 2021, correct? I’ve heard similar if not worse numbers as well. Seems that a couple of these funds have posted similar returns YTD for 2022, especially after a brutal April. Incredible how biotech went from a safe haven to its current state.

 

Reiciendis et aut fugiat ducimus vero nobis. Corrupti autem est nemo asperiores et. Aliquid distinctio debitis repellendus vero maxime vel.

Veritatis qui placeat nesciunt et doloribus. Eum et veniam vel explicabo. Voluptate dolorem est consequatur neque optio blanditiis. Optio sunt explicabo atque eligendi sed. Pariatur consequatur ea enim numquam omnis sunt omnis. Assumenda et reprehenderit alias sapiente deserunt autem. Fuga et iusto numquam autem est ut ipsam et.

Rerum voluptate nostrum necessitatibus autem labore nemo ab. Ex eos omnis aut sint enim similique. Saepe nostrum iure quia eos sit iusto.

Career Advancement Opportunities

March 2024 Hedge Fund

  • Point72 98.9%
  • D.E. Shaw 97.9%
  • Magnetar Capital 96.8%
  • Citadel Investment Group 95.8%
  • AQR Capital Management 94.7%

Overall Employee Satisfaction

March 2024 Hedge Fund

  • Magnetar Capital 98.9%
  • D.E. Shaw 97.8%
  • Blackstone Group 96.8%
  • Two Sigma Investments 95.7%
  • Citadel Investment Group 94.6%

Professional Growth Opportunities

March 2024 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 97.9%
  • D.E. Shaw 96.9%
  • Citadel Investment Group 95.8%
  • Magnetar Capital 94.8%

Total Avg Compensation

March 2024 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (23) $474
  • Director/MD (12) $423
  • NA (6) $322
  • 3rd+ Year Associate (24) $287
  • Manager (4) $282
  • Engineer/Quant (71) $274
  • 2nd Year Associate (30) $251
  • 1st Year Associate (73) $190
  • Analysts (225) $179
  • Intern/Summer Associate (22) $131
  • Junior Trader (5) $102
  • Intern/Summer Analyst (249) $85
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
kanon's picture
kanon
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
DrApeman's picture
DrApeman
98.9
9
GameTheory's picture
GameTheory
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”